Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Arch Pediatr ; 25(8): 464-468, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-30340941

RESUMO

BACKGROUND: Infection is the major cause of treatment-related mortality in childhood acute leukemia, mainly due to bacterial translocation across the intestinal mucosa. Only a few studies have reported the impact of different antibacterial prophylaxis treatments on digestive tract flora and infection-related mortality. PROCEDURES: We performed a retrospective analysis of two different digestive tract decontamination modalities (selective or total digestive decontamination) in a large single-center series of 323 children during the induction treatment of acute leukemia between January 1995 and December 2014. We examined the impact of antibiotic prophylaxis and food regimen (sterile or selected) on the digestive tract flora during the period of antibacterial prophylaxis, on the frequency of bacteremia, and on antibiotic sensitivity. RESULTS: Only one Gram-negative (Klebsiella pneumonia) translocation occurred in the SDD group. No infection-related death occurred. Extended-spectrum beta-lactamase (ESBL) bacteria were observed in seven of 170 (4%) patients in the SDD group. The faecal-flora total suppression and faecal-flora Gram-negative bacilli suppression was 67 and 77%, respectively, in the TDD group with sterile food, 0 and 58%, respectively, in the SDD group with sterile food, and 6 and 63%, respectively, in the SDD group with selective food. CONCLUSIONS: This study gives a rationale not to use antibacterial prophylaxis systematically in children who receive induction treatment for acute leukemia; additionally, antibiotics should only be used in case of stool contamination by highly pathogenic bacteria with a high potential of translocation.


Assuntos
Antibacterianos/uso terapêutico , Antibioticoprofilaxia/métodos , Microbioma Gastrointestinal/efeitos dos fármacos , Leucemia/tratamento farmacológico , Doença Aguda , Adolescente , Antibacterianos/efeitos adversos , Antibioticoprofilaxia/efeitos adversos , Bacteriemia/microbiologia , Criança , Pré-Escolar , Descontaminação/métodos , Feminino , Humanos , Quimioterapia de Indução , Lactente , Leucemia/complicações , Masculino , Estudos Retrospectivos
2.
Bone Marrow Transplant ; 50(11): 1438-44, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26191949

RESUMO

We evaluated prospectively the incidence and risk factors of the metabolic syndrome (MS) and its components in 170 adult patients (mean age at evaluation: 24.8±5.4 years) who received an hematopoietic stem cell transplantation for childhood ALL, n=119, or AML, n=51. TBI was carried out in 124 cases; a busulfan-based conditioning was done in 30 patients. Twenty-nine patients developed a MS (17.1%, 95% confidence intervals: 11.7-23.6). The cumulative incidence was 13.4% at 25 years of age and 35.5% at 35 years of age. A higher body mass index (BMI) before transplantation and a growth hormone deficiency were associated with increased MS risk (P=0.002 and 0.01, respectively). MS risk was similar for patients who received TBI or busulfan-based conditioning. The TBI use increased the hyperglycemia risk (odds ratio (OR): 4.7, P=0.02). Women were at the risk of developing increased waist circumference (OR: 7.18, P=0.003) and low levels of high-density lipoprotein cholesterol (OR: 2.72, P=0.007). The steroid dose was not a risk factor. The MS occurs frequently among transplanted survivors of childhood leukemia. Its incidence increases with age. Both intrinsic (BMI, gender) and extrinsic factors (TBI, alkylating agents) contribute to its etiopathogenesis.


Assuntos
Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Síndrome Metabólica/etiologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Sobreviventes , Condicionamento Pré-Transplante/efeitos adversos , Corticosteroides/administração & dosagem , Corticosteroides/efeitos adversos , Adulto , Antineoplásicos Alquilantes/efeitos adversos , Antineoplásicos Alquilantes/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Glicemia/análise , Índice de Massa Corporal , Bussulfano/uso terapêutico , HDL-Colesterol/sangue , Terapia Combinada , Feminino , Humanos , Lipídeos/sangue , Masculino , Síndrome Metabólica/sangue , Agonistas Mieloablativos/efeitos adversos , Agonistas Mieloablativos/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Modelos de Riscos Proporcionais , Estudos Prospectivos , Fatores de Risco , Fatores Sexuais , Circunferência da Cintura , Irradiação Corporal Total/efeitos adversos , Adulto Jovem
3.
Bone Marrow Transplant ; 49(5): 709-16, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24535128

RESUMO

The purpose of this multicenter study was to compare the long-term impact of a preparative regimen with either BUBU or TBI on health status and quality of life (QoL) in childhood acute leukemia survivors treated with hematopoietic SCT (HSCT). Two-hundred and forty patients were included. Sixty-six had received BU, while 174 had received TBI. Median follow-up from HSCT was 10.1 years. Multivariate analyses were performed to assess the occurrence of late effects according to treatment. QoL was assessed in 130 adults using SF-36 questionnaires. Patients developed fewer late complications after BU (2.35 vs 3.01, P=0.03) while the risk to present with at least one complication was equivalent in both groups (87.9% after BU and 93.1% after TBI, P=0.66). Detailed multivariate analyses revealed a lower risk of height growth failure (OR=0.2), cataract (OR=0.1) and iron overload (OR=0.2) after BU, and an increased risk of overweight (OR=3.9) and alopecia (OR=11.2). SF-36 mental and physical composite scores were similar in both treatment groups and proved significantly lower than French norms. Late effects induced by BU might differ from those experienced after TBI. Although less frequent, they are still of considerable importance and may affect patients' QoL.


Assuntos
Bussulfano/efeitos adversos , Nível de Saúde , Transplante de Células-Tronco Hematopoéticas , Leucemia Mieloide Aguda/terapia , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Irradiação Corporal Total , Adolescente , Bussulfano/administração & dosagem , Catarata/induzido quimicamente , Criança , Pré-Escolar , Feminino , Seguimentos , Transtornos do Crescimento/induzido quimicamente , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/efeitos adversos , Lactente , Sobrecarga de Ferro/induzido quimicamente , Masculino , Sobrepeso/induzido quimicamente , Qualidade de Vida , Sobreviventes , Tempo
4.
Bone Marrow Transplant ; 47(5): 684-93, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-21725370

RESUMO

The literature contains a substantial amount of information about factors that adversely influence the linear growth in up to 85% of patients undergoing haematopoietic SCT (HSCT) with TBI and/or cranial irradiation (CI) for acute leukaemia (AL). By contrast, only a few studies have evaluated the impact of growth hormone (GH) therapy on growth rate and final height (FH) in these children. We evaluated growth rates during the pre- and post-transplant periods to FH in a group of 25 children treated with HSCT (n=22), TBI (n=21) or/and CI (n=8) for AL and receiving GH therapy. At the start of GH treatment, the median height Z-score was -2.19 (-3.95 to 0.02), significantly lower than at AL diagnosis (P<0.001). Overall height gain from start of GH treatment to FH was 0.59Z (-2.72 to 2.93) with a median height Z-score at FH of -1.35 (-5.35 to 0.27). This overall height gain effect was greater in girls than in boys (P=0.04). The number of children with heights in the reference population range was greater after than before GH therapy (P=0.07). At FH the GVHD and GH treatments lasting <2 years were associated with shorter FH (P=0.02 and 0.05). We found a measurable beneficial effect of GH treatment on growth up to FH.


Assuntos
Estatura/efeitos dos fármacos , Estatura/efeitos da radiação , Irradiação Craniana/efeitos adversos , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Hormônio do Crescimento Humano/administração & dosagem , Leucemia Mieloide Aguda/terapia , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Irradiação Corporal Total/efeitos adversos , Criança , Pré-Escolar , Feminino , Seguimentos , Hormônio do Crescimento Humano/deficiência , Humanos , Lactente , Masculino , Estudos Retrospectivos
5.
Bone Marrow Transplant ; 43(8): 637-42, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19011662

RESUMO

We compared the impact of a conditioning regimen with BU (n=16) or fractionated TBI (n=42) on height growth during adolescence and final height (FH), in 58 adults transplanted for acute leukaemia before adolescence (younger than 9 for girls and 11 for boys, and prepubertal). Heights were measured at three key periods, that is, transplantation, before adolescence, and FH, and compared using height standard deviation score (SDS) and cumulative change in SDS. The influence of the conditioning regimen was assessed using multiple linear regression and adjusting for gender, central nervous system irradiation, age and leukaemia status at transplant and type of transplantation. Overall mean height SDS was near normal at transplantation and before adolescence (0.2+/-0.1 and -0.2+/-0.1, respectively), but decreased to -1.6+/-0.1 at FH. There were significant differences between the TBI and BU groups when comparing FH SDS (-1.8+/-0.2 vs -0.8+/-0.2, P=0.001), mean change in height SDS from transplantation to FH (-2+/-0.1 vs -1.1+/-0.2, P=0.002) and mean change in height SDS during adolescence (-1.6+/-0.1 vs -0.7+/-0.2, P=0.003). We conclude that preparations involving BU, although less toxic than TBI-containing regimens, also have adverse effects on growth, predominantly during adolescence.


Assuntos
Transplante de Células-Tronco Hematopoéticas/métodos , Leucemia Mieloide Aguda/fisiopatologia , Leucemia Mieloide Aguda/terapia , Leucemia-Linfoma Linfoblástico de Células Precursoras/fisiopatologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Condicionamento Pré-Transplante/métodos , Adolescente , Estatura , Criança , Feminino , Transtornos do Crescimento/etiologia , Humanos , Masculino , Indução de Remissão , Fatores de Tempo , Resultado do Tratamento , Irradiação Corporal Total
6.
Acta Anaesthesiol Belg ; 44(1): 17-23, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-8342400

RESUMO

The aim of this study was to examine the value of systematic preoperative pulmonary function tests (PFTs) in order to reliably predict prolonged stay in I.C.U., prolonged mechanical ventilation and mortality in elective cardiac surgical patients. 149 consecutive adult patients (valvular replacement or coronary bypass graft) were studied retrospectively. We examined the preoperative respiratory data: vital capacity (VC), first second forced expired volume (FEV1), PaCO2 and PO2. Length of stay in I.C.U. (LICU), duration of mechanical ventilation (DMV), incidence of reintubation and survival rate were used as indices of respiratory morbidity. The results of the present study clearly indicate that patients with impaired airway flow rates had a prolonged postoperative recovery following cardiac surgery. Mortality, ICV and DMV increased when FEV1 was less than 1.5 L, VC was less than 2.5 L, or PaO2 was less than 8.5 kPa. Reintubation was associated with impaired flow rates. Pulmonary function tests appeared effective in predicting postoperative complications and the need for prolonged ventilatory support.


Assuntos
Procedimentos Cirúrgicos Cardíacos , Cuidados Pré-Operatórios , Testes de Função Respiratória , Procedimentos Cirúrgicos Cardíacos/mortalidade , Feminino , Volume Expiratório Forçado , Humanos , Unidades de Terapia Intensiva , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Oxigênio/sangue , Valor Preditivo dos Testes , Respiração Artificial , Estudos Retrospectivos , Taxa de Sobrevida , Capacidade Vital
8.
J Immunol Methods ; 9(1): 27-38, 1975 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-812918

RESUMO

Polyacrylamide beads antibody immunoabsorbents were used in order to isolate human IgA, IgM and fragments of papain-digested human IgG. The proteins obtained were pure as judged by immunochemical techniques. The antisera raised with these purified proteins were monospecific. The binding capacity and the yield were satisfactory. These antibody immunoadsorbents offer several advantages; a) highly purified antigens can be quickly obtained in a one-step procedure from body fluids; b) their handling is easy especially when using a column; c) they can be used for a long period of time and for many experiments without any noticeable loss in their binding capacity.


Assuntos
Acrilamidas , Imunoglobulina A/isolamento & purificação , Fragmentos de Imunoglobulinas/isolamento & purificação , Imunoglobulina G/análise , Imunoglobulina M/isolamento & purificação , Absorção , Anticorpos Anti-Idiotípicos , Disgamaglobulinemia/imunologia , Humanos , Imunoglobulina A Secretora/isolamento & purificação , Cadeias alfa de Imunoglobulina , Cadeias mu de Imunoglobulina , Mieloma Múltiplo/imunologia , Macroglobulinemia de Waldenstrom/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...